Gene-Specific Template (Updated 9-28-21) - Revision history

Jennelleh at 19:22, 28 September 2021

2021-09-28T19:22:36Z

← Older revision		Revision as of 14:22, 28 September 2021
Line 1:		Line 1:
	{{Under Construction}}		{{Under Construction}}

	(''General Instructions –The main focus of these pages is providing a quick reference for cancer associations and linking to internal and external resources providing genetics-related information for the gene of interest. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/recommendations/DNA/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them. The use of bullet points rather than large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author Instructions\|<u>Author Instructions</u>]] , [[How to Curate a Gene Page]], and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [Mailto:CCGA@cancergenomics.org <u>Technical Support</u>].'')		(''General Instructions –The main focus of these pages is providing a quick reference for cancer associations and linking to internal and external resources providing genetics-related information for the gene of interest. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/recommendations/DNA/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them. The use of bullet points rather than large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author Instructions\|<u>Author Instructions</u>]] , [[How to Curate a Gene Page\|<u>How to Curate a Gene Page</u>]], and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [Mailto:CCGA@cancergenomics.org <u>Technical Support</u>].'')

	==Primary Author(s)*==		==Primary Author(s)*==

Jennelleh at 19:22, 28 September 2021

2021-09-28T19:22:22Z

← Older revision		Revision as of 14:22, 28 September 2021
Line 1:		Line 1:
	{{Under Construction}}		{{Under Construction}}

	(''General Instructions –The main focus of these pages is providing a quick reference for cancer associations and linking to internal and external resources providing genetics-related information for the gene of interest. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/recommendations/DNA/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them. The use of bullet points rather than large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author Instructions\|<u>Author Instructions</u>]] and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [Mailto:CCGA@cancergenomics.org <u>Technical Support</u>].'')		(''General Instructions –The main focus of these pages is providing a quick reference for cancer associations and linking to internal and external resources providing genetics-related information for the gene of interest. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/recommendations/DNA/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them. The use of bullet points rather than large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author Instructions\|<u>Author Instructions</u>]] , [[How to Curate a Gene Page]], and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [Mailto:CCGA@cancergenomics.org <u>Technical Support</u>].'')

	==Primary Author(s)*==		==Primary Author(s)*==
Line 97:		Line 97:
	==External Links==		==External Links==

	Put your text here (''Instruction: Include as applicable links to:		Put your text here (''Instruction: Include as applicable links to: ''
	1) Atlas of Genetics and Cytogenetics in Oncology and Haematology,		1) Atlas of Genetics and Cytogenetics in Oncology and Haematology,
	2) COSMIC,		2) COSMIC,
Line 114:		Line 114:
	15) TICdb - database of Translocation breakpoints In Cancer		15) TICdb - database of Translocation breakpoints In Cancer
	16) GeneReviews,		16) GeneReviews,
	17) ClinGen, and 18) Any gene-specific databases''.)		17) ClinGen, and 18) Any gene-specific databases''.)''

	EXAMPLES (these may be filled in already and if not, click on the link and select edit to change)		EXAMPLES (these may be filled in already and if not, click on the link and select edit to change)

Jennelleh at 19:05, 28 September 2021

2021-09-28T19:05:14Z

← Older revision		Revision as of 14:05, 28 September 2021
Line 97:		Line 97:
	==External Links==		==External Links==

	Put your text here - Include as applicable links to:		Put your text here (''Instruction: Include as applicable links to:
	1) Atlas of Genetics and Cytogenetics in Oncology and Haematology,		1) Atlas of Genetics and Cytogenetics in Oncology and Haematology,
	2) COSMIC,		2) COSMIC,
Line 114:		Line 114:
	15) TICdb - database of Translocation breakpoints In Cancer		15) TICdb - database of Translocation breakpoints In Cancer
	16) GeneReviews,		16) GeneReviews,
	17) ClinGen, and 18) Any gene-specific databases.		17) ClinGen, and 18) Any gene-specific databases''.)

	EXAMPLES (these may be filled in already and if not, click on the link and select edit to change)		EXAMPLES (these may be filled in already and if not, click on the link and select edit to change)
Line 159:		Line 159:

	==References==		==References==
	(~~use~~ "Cite" icon at top of page for automatic insertion using PMID; ''If a PMID is not available, manually add the reference information such as for the example book or internet resource below'')<references />		(''Instruction: Use "Cite" icon at top of page for automatic insertion using PMID;'' ''If a PMID is not available, manually add the reference information such as for the example book or internet resource below'')<references />
	===EXAMPLE Book===		===EXAMPLE Book===

Jennelleh at 19:03, 28 September 2021

2021-09-28T19:03:09Z

← Older revision		Revision as of 14:03, 28 September 2021
Line 116:		Line 116:
	17) ClinGen, and 18) Any gene-specific databases.		17) ClinGen, and 18) Any gene-specific databases.

	EXAMPLES (these may be filled in already)		EXAMPLES (these may be filled in already and if not, click on the link and select edit to change)

	'''[http://atlasgeneticsoncology.org/Genes/P53ID88.html ''TP53'' by Atlas of Genetics and Cytogenetics in Oncology and Haematology]''' - detailed gene information		'''[http://atlasgeneticsoncology.org/Genes/P53ID88.html ''TP53'' by Atlas of Genetics and Cytogenetics in Oncology and Haematology]''' - detailed gene information

Jennelleh at 19:01, 28 September 2021

2021-09-28T19:01:57Z

← Older revision		Revision as of 14:01, 28 September 2021
Line 159:		Line 159:

	==References==		==References==
	(''~~Instruction: Add PMIDs into the text above where references are appropriate - PMIDs will be used to insert references on the CCGA site and the reference list automatically generated'')~~		(use "Cite" icon at top of page for automatic insertion using PMID; ''If a PMID is not available, manually add the reference information such as for the example book or internet resource below'')<references />

	~~(''Instruction:~~ If a PMID is not available, such as for a book~~, please include the entire reference in this section~~'')<references />
	===EXAMPLE Book===		===EXAMPLE Book===

Jennelleh at 18:59, 28 September 2021

2021-09-28T18:59:02Z

← Older revision		Revision as of 13:59, 28 September 2021
Line 159:		Line 159:

	==References==		==References==
	(~~use "Cite" icon at top of page~~)		(''Instruction: Add PMIDs into the text above where references are appropriate - PMIDs will be used to insert references on the CCGA site and the reference list automatically generated'')
	<references />
			(''Instruction: If a PMID is not available, such as for a book, please include the entire reference in this section'')<references />
	===EXAMPLE Book===		===EXAMPLE Book===

Line 166:		Line 167:

	===EXAMPLE Internet Resource===		===EXAMPLE Internet Resource===
			Author name(s). Date (if possible). page title, website title, web address, and date accessed.

	~~#author name(s). Date (if possible). page title, website title, web address, and date accessed.~~
	#Cingam, S. R. and Koshy, N.V. (2017). Cancer, Leukemia, Promyelocytic, Acute (APL, APML). https://www.ncbi.nlm.nih.gov/books/NBK459352/ Accessed August 3, 2018.		#Cingam, S. R. and Koshy, N.V. (2017). Cancer, Leukemia, Promyelocytic, Acute (APL, APML). https://www.ncbi.nlm.nih.gov/books/NBK459352/ Accessed August 3, 2018.

	==Notes==		==Notes==
	<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.		<nowiki>*</nowiki>Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.

Jennelleh at 18:56, 28 September 2021

2021-09-28T18:56:45Z

← Older revision		Revision as of 13:56, 28 September 2021
Line 36:		Line 36:
	EXAMPLE:		EXAMPLE:

	* ''TP53'' is a well-described tumor suppressor gene that functions in apoptosis, genomic stability and inhibition of angiogenesis (RefSeq, Dec 2016).		*''TP53'' is a well-described tumor suppressor gene that functions in apoptosis, genomic stability and inhibition of angiogenesis (RefSeq, Dec 2016).
	* Germline loss-of-function alterations, including deletions, are associated with Li-Fraumeni cancer predisposition syndrome (LFS). Individuals with LFS are at an increased risk of developing cancer, particularly sarcomas (PMID: 20586629, 27621308, 25896519).		*Germline loss-of-function alterations, including deletions, are associated with Li-Fraumeni cancer predisposition syndrome (LFS). Individuals with LFS are at an increased risk of developing cancer, particularly sarcomas (PMID: 20586629, 27621308, 25896519).
	* Somatic ''TP53'' alterations are reported at a high frequency across a wide range of tumors, arising in ~30% of all cancer patients (PMID: 25400752, 27239089, cbioportal.org accessed 6/2/21).		*Somatic ''TP53'' alterations are reported at a high frequency across a wide range of tumors, arising in ~30% of all cancer patients (PMID: 25400752, 27239089, cbioportal.org accessed 6/2/21).

	==Clinical Cancer Associations (Somatic)==		==Clinical Cancer Associations (Somatic)==
			(''Instruction: include references and links to related internal CCGA pages'')
	{\| class="wikitable"		{\| class="wikitable"
	\|'''Tumor Type'''		\|'''Tumor Type'''
Line 48:		Line 49:
	\|'''Therapeutic Significance (Yes, No or Unknown)'''		\|'''Therapeutic Significance (Yes, No or Unknown)'''
	\|-		\|-
	\|EXAMPLE: Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive (link to internal page ~~through this name~~)		\|EXAMPLE: Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive (link this name to internal page using link icon above)
	\|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion, Expression Changes (Biomarker), Somatic Hypermutation		\|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion, Expression Changes (Biomarker), Somatic Hypermutation
	\|		\|
Line 68:		Line 69:

	==Clinical Cancer Associations (Germline)==		==Clinical Cancer Associations (Germline)==
			(''Instruction: include references and links to related internal CCGA pages'')
	{\| class="wikitable"		{\| class="wikitable"
	\|'''Tumor Type'''		\|'''Tumor Type'''
Line 75:		Line 77:
	\|'''Therapeutic Significance (Yes, No or Unknown)'''		\|'''Therapeutic Significance (Yes, No or Unknown)'''
	\|-		\|-
	\|EXAMPLE: Myeloid Neoplasms with Germline ANKRD26 Mutation (link to internal page ~~through this name~~)		\|EXAMPLE: Myeloid Neoplasms with Germline ANKRD26 Mutation (link this name to internal page using link icon above)
	\|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion,		\|EXAMPLES: Copy Number Loss, Copy Number Gain, LOH, Loss-of-Function Mutation, Gain-of-Function Mutation, Translocation/Fusion,
	\|		\|
Line 87:		Line 89:
	\|		\|
	\|-		\|-
	\|
	\|
	\|
	\|
	\|
	\|}		\|}

Jennelleh at 18:52, 28 September 2021

2021-09-28T18:52:10Z

← Older revision		Revision as of 13:52, 28 September 2021
Line 28:		Line 28:
	==Gene in Cancer Overview==		==Gene in Cancer Overview==

	* Put your text here		*Put your text here
	* Put your text here		*Put your text here
	* Put your text here		*Put your text here

	(''Instruction: Use a list of three bullets, targeting one to three sentences each for gene function, germline associations, and somatic associations. Include gene/protein function in cancer such as tumor suppressor, oncogene or other. The information provided can include high level clinically significant details such as if mutations in this gene confirm or exclude certain diseases. Of note, this gene page is not meant to recapitulate the very detailed content on related linked disease entity pages.'')		(''Instruction: Use a list of three bullets, targeting one to three sentences each for gene function, germline associations, and somatic associations. Include gene/protein function in cancer such as tumor suppressor, oncogene or other. The information provided can include high level clinically significant details such as if mutations in this gene confirm or exclude certain diseases. Of note, this gene page is not meant to recapitulate the very detailed content on related linked disease entity pages.'')

			EXAMPLE:

			* ''TP53'' is a well-described tumor suppressor gene that functions in apoptosis, genomic stability and inhibition of angiogenesis (RefSeq, Dec 2016).
			* Germline loss-of-function alterations, including deletions, are associated with Li-Fraumeni cancer predisposition syndrome (LFS). Individuals with LFS are at an increased risk of developing cancer, particularly sarcomas (PMID: 20586629, 27621308, 25896519).
			* Somatic ''TP53'' alterations are reported at a high frequency across a wide range of tumors, arising in ~30% of all cancer patients (PMID: 25400752, 27239089, cbioportal.org accessed 6/2/21).

	==Clinical Cancer Associations (Somatic)==		==Clinical Cancer Associations (Somatic)==

Jennelleh at 18:51, 28 September 2021

2021-09-28T18:51:02Z

← Older revision		Revision as of 13:51, 28 September 2021
Line 5:		Line 5:
	==Primary Author(s)*==		==Primary Author(s)*==

	Put your text here		Put your text here (''Name and affiliation; EXAMPLE: Jane Smith, PhD, Institute of Genomics'')
	EXAMPLE: Jane Smith, PhD, Institute of Genomics

	__TOC__		__TOC__
Line 29:		Line 28:
	==Gene in Cancer Overview==		==Gene in Cancer Overview==

	Put your text here		* Put your text here
			* Put your text here
			* Put your text here

			(''Instruction: Use a list of three bullets, targeting one to three sentences each for gene function, germline associations, and somatic associations. Include gene/protein function in cancer such as tumor suppressor, oncogene or other. The information provided can include high level clinically significant details such as if mutations in this gene confirm or exclude certain diseases. Of note, this gene page is not meant to recapitulate the very detailed content on related linked disease entity pages.'')

	==Clinical Cancer Associations (Somatic)==		==Clinical Cancer Associations (Somatic)==

Jennelleh at 18:39, 28 September 2021

2021-09-28T18:39:46Z

← Older revision		Revision as of 13:39, 28 September 2021
Line 1:		Line 1:
	{{Under Construction}}		{{Under Construction}}

	(''General Instructions –The main focus of these pages is providing a quick reference for cancer associations and linking to internal and external resources providing genetics-related information for the gene of interest. Use [https://www.genenames.org/ HUGO-approved gene names and symbols] (italicized when appropriate), [https://varnomen.hgvs.org/recommendations/DNA/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them. The use of bullet points rather than large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author Instructions]] and [[Frequently Asked Questions (FAQs)\|FAQs]] as well as contact your [[Leadership\|Associate Editor]] or ~~'''~~[Mailto:CCGA@cancergenomics.org <u>Technical Support</u>]~~'''~~.'')		(''General Instructions –The main focus of these pages is providing a quick reference for cancer associations and linking to internal and external resources providing genetics-related information for the gene of interest. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/recommendations/DNA/ <u>HGVS-based nomenclature for variants</u>], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them. The use of bullet points rather than large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see [[Author Instructions\|<u>Author Instructions</u>]] and [[Frequently Asked Questions (FAQs)\|<u>FAQs</u>]] as well as contact your [[Leadership\|<u>Associate Editor</u>]] or [Mailto:CCGA@cancergenomics.org <u>Technical Support</u>].'')

	==Primary Author(s)*==		==Primary Author(s)*==